SCHEMBL758590

SCHEMBL758590

NOCC(O)CON

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL11135283 0.96 THRB (0.32)
SCHEMBL3971564 0.85
SCHEMBL514670 0.83
SCHEMBL236251 0.83
SCHEMBL13745145 0.83
SCHEMBL13745144 0.83
SCHEMBL15624617 0.83
SCHEMBL2565232 0.83
SCHEMBL18973986 0.81
SCHEMBL22789862 0.81

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106535876-B Multivalent delivery of immunomodulators through liposomal spherical nucleic acids for prophylactic or therapeutic applications 埃克西奎雷股份有限公司 2020-09-11 CN claimed
EP-3084433-B1 METHOD OF IMMOBILIZING A CELL ON A SUPPORT USING COMPOUNDS COMPRISING A POLYETHYLENE GLYCOL MOIETY ROCHE DIAGNOSTICS GMBH (DE) 2020-03-18 EP claimed
EP-3164113-B1 MULTIVALENT DELIVERY OF IMMUNE MODULATORS BY LIPOSOMAL SPHERICAL NUCLEIC ACIDS FOR PROPHYLACTIC OR THERAPEUTIC APPLICATIONS EXICURE INC (US) 2019-03-27 EP claimed
EP-3084431-B1 COMPOUNDS COMPRISING ONE OR MORE HYDROPHOBIC DOMAINS AND A HYDROPHILIC DOMAIN COMPRISING PEG MOIETIES, USEFUL FOR BINDING CELLS ROCHE DIAGNOSTICS GMBH (DE) 2018-11-07 EP claimed
US-20160355859-A1 TRANSGLUTAMINASE MEDIATED CONJUGATION OF PEPTIDES NOVO NORDISK A/S (DK) 2016-12-08 US claimed
EP-2033662-B1 Transglutaminase mediated conjugation of peptides NOVO NORDISK HEALTHCARE AG (CH) 2012-10-17 EP claimed
EP-2368579-A1 Transglutaminase mediated conjugation of peptides Novo Nordisk Health Care AG (CH) 2011-09-28 EP claimed
US-20100009917-A1 Modulating Enzymatic Processes by Addition of Diolcontaining Substances NOVO NORDISK HEALTH CARE AG (CH) 2010-01-14 US claimed
US-20090264366-A1 Transglutaminase Mediated Conjugation of Peptides NOVO NORDISK HEALTHCARE AG (CH) 2009-10-22 US claimed
EP-2033662-A1 Transglutaminase mediated conjugation of peptides Novo Nordisk Health Care AG (CH) 2009-03-11 EP claimed
US-20070105770-A1 Transglutaminase mediated conjugation of peptides NOVO NORDISK A/S (DK) 2007-05-10 US claimed
US-11965886-B2 Method of immobilizing a cell on a support using compounds comprising a polyethylene glycol moiety ROCHE DIAGNOSTICS OPERATIONS, INC. (US) 2024-04-23 US disclosed
WO-2022210788-A1 PHOTOSENSITIVE RESIN COMPOSITION 味の素株式会社 2022-10-06 WO disclosed
CN-106535876-B Multivalent delivery of immunomodulators through liposomal spherical nucleic acids for prophylactic or therapeutic applications 埃克西奎雷股份有限公司 2020-09-11 CN disclosed
EP-2842576-B1 Transglutaminase mediated conjugation of peptides NOVO NORDISK HEALTHCARE AG (CH) 2017-06-28 EP disclosed
US-20060154984-A1 Therapeutic use of acyl glycerols and the nitrogen- and sulphur- containing analogues thereof GENFIT (FR) 2006-07-13 US disclosed
US-20060069156-A1 Acylated aminopropanediols and analogues and therapeutic uses thereof GENFIT (FR) 2006-03-30 US disclosed
US-20060035977-A1 Uses of acylated aminopropanediols and sulphur and nitrogen analogues of same f GENTIF (FR) 2006-02-16 US disclosed
EP-1596845-A1 THERAPEUTIC USE OF ACYL GLYCEROLS AND THE NITROGEN- AND SULPHUR-CONTAINING ANALOGUES THEROF Genfit (FR) 2005-11-23 EP disclosed
WO-2004073698-A1 THERAPEUTIC USE OF ACYL GLYCEROLS AND THE NITROGEN- AND SULPHUR-CONTAINING ANALOGUES THEROF GENFIT (FR) 2004-09-02 WO disclosed